Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine(PNEU-PLAN)

Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.

Research

DETECT Schools Study Protocol: A Prospective Observational Cohort Surveillance Study Investigating the Impact of COVID-19 in Western Australian Schools

Amidst the evolving COVID-19 pandemic, understanding the transmission dynamics of the SARS-CoV-2 virus is key to providing peace of mind for the community and informing policy-making decisions. While available data suggest that school-aged children are not significant spreaders of SARS-CoV-2, the possibility of transmission in schools remains an ongoing concern, especially among an aging teaching workforce. Even in low-prevalence settings, communities must balance the potential risk of transmission with the need for students' ongoing education.

Research

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

Research

An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers

Adult pertussis vaccination is increasingly recommended to control pertussis in the community. However, there is little data on the duration and kinetics of immunity to pertussis boosters in adults. We compared IgG responses to vaccination with a tetanus, low-dose diphtheria, low-dose acellular pertussis (Tdap) booster at 1 week, 1 month and 1 year post-vaccination in whole-cell (wP)-primed Australian paediatric healthcare workers who had received an adult Tdap booster 5-12 years previously, to those who received their first Tdap booster. Tdap vaccination was well tolerated in both groups.

Research

An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers

Adult pertussis vaccination is increasingly recommended to control pertussis in the community. However, there is little data on the duration and kinetics of immunity to pertussis boosters in adults. We compared IgG responses to vaccination with a tetanus, low-dose diphtheria, low-dose acellular pertussis (Tdap) booster at 1 week, 1 month and 1 year post-vaccination in whole-cell (wP)-primed Australian paediatric healthcare workers who had received an adult Tdap booster 5-12 years previously, to those who received their first Tdap booster.

News & Events

Early ear infections linked to higher risk of future problems: study

Researchers have found kids who experience repeat ear infections in infancy have a much higher risk of ongoing problems with ear infections in later childhood

News & Events

Round one done, eight to go for the SToP Trial

Six weeks, nine community visits and 380 kids – it’s a wrap for round one of the StoP Trial!

News & Events

WA Health funding supports development of rapid test for antibiotic-resistant skin infections in Aboriginal children

A rapid test to detect antibiotic-resistant skin infections in Aboriginal children could be a step closer, thanks to support from the FHRIF.

News & Events

World-first trial to seek child-specific treatments for dangerous bloodstream infections

The Kids Research Institute Australia, Perth Children’s Hospital (PCH) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) will spearhead the paediatric arm of a world-first global platform trial designed to uncover treatments for Staphylococcus aureus bloodstream infection.

News & Events

Flu study gives vital early protection to bubs this winter

The FluBub Study will investigate whether giving the flu vaccine much earlier than the six months currently recommended by the National Immunisation Program will protect babies at the greatest risk of a severe influenza infection when they are most vulnerable.